OncoMatch/Clinical Trials/NCT05568550
Pembro With Radiation With or Without Olaparib
Is NCT05568550 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Olaparib for prostate cancer.
Treatment: Pembrolizumab · Olaparib · Androgen Deprivation Therapy — This trial will evaluate whether the immune-sensitizing effects of immunotherapy (Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the effects of immunotherapy in men with high-risk localized prostate cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Prostate Cancer
Disease stage
Required: Stage HIGH-RISK, VERY HIGH-RISK (NCCN)
High-risk / very high-risk status per NCCN guidelines; Patients with M1 disease [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: LHRH agonist (Lupron)
Exception: allowed only if onset ≤90 days prior to registration
Prior hormonal therapy with LHRH agonists (e.g., Lupron) for prostate cancer continuously for more than 90-days prior to study enrollment.
Cannot have received: LHRH antagonist (Degarelix)
Exception: allowed only if onset ≤90 days prior to registration
Prior hormonal therapy with LHRH antagonists (e.g., Degarelix) for prostate cancer continuously for more than 90-days prior to study enrollment.
Cannot have received: radiation therapy
Prior radiation to the prostate or pelvic nodes radiation.
Cannot have received: systemic anti-cancer therapy
Exception: within 4 weeks prior to randomization
Prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to randomization.
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ and marrow function. Known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Kentucky · Lexington, Kentucky
- Huntsman Cancer Institute · Salt Lake City, Utah
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05568550 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior LHRH agonist, LHRH antagonist, radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage HIGH-RISK or VERY HIGH-RISK is required.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages